Last reviewed · How we verify
Bronchial fibroscopy
Bronchial fibroscopy is a Biologic drug developed by CMC Ambroise Paré. It is currently in Phase 2 development for Diagnosis of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.
Bronchial fibroscopy is a diagnostic procedure that uses a flexible tube with a camera and light to visually examine the airways and lungs.
Bronchial fibroscopy is a medical procedure used to study conditions such as chronic obstructive pulmonary disease (COPD), severe asthma, and asthma in children. It involves the use of a bronchoscope to examine the airways, and has been used in conjunction with interventions such as sitaxentan, a muscarinic acetylcholine receptor M3 agonist, in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bronchial fibroscopy |
|---|---|
| Sponsor | CMC Ambroise Paré |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
The procedure involves inserting the flexible tube through the nose or mouth and guiding it through the airways to the lungs. This allows for the examination of the airway walls, bronchial tubes, and lung tissue for signs of disease or damage.
Approved indications
- Diagnosis of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer
Common side effects
Key clinical trials
- Global Physiotherapy in ICU Patients With High Risk Extubation Failure (NA)
- Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS) (NA)
- Evaluation of Virtual Reality to Reduce Anxiety, Pain and Duration of Non-emergency Vigile Bronchial Fibroscopy (AVATAR) (NA)
- Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS
- Analysis of Bronchial Remodeling Using Resonance Magnetic Imaging in Severe Asthmatic childrEn (NA)
- Thymic Function in Patients With COVID-19
- DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection (NA)
- Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bronchial fibroscopy CI brief — competitive landscape report
- Bronchial fibroscopy updates RSS · CI watch RSS
- CMC Ambroise Paré portfolio CI
Frequently asked questions about Bronchial fibroscopy
What is Bronchial fibroscopy?
How does Bronchial fibroscopy work?
What is Bronchial fibroscopy used for?
Who makes Bronchial fibroscopy?
What development phase is Bronchial fibroscopy in?
Related
- Manufacturer: CMC Ambroise Paré — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Diagnosis of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing